A 12-month Real Life Study of IBD Patients Under Stable Steroid Free Clinical and Biological Remission Switched From Adalimumab Originator Humira® to One of Its Biosimilar: Amgevita®,Hulio®,Hyrimoz® or Imraldi®.
Latest Information Update: 03 Feb 2023
At a glance
- Drugs Adalimumab (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Therapeutic Use
- Acronyms Rhoneswitch
Most Recent Events
- 28 Sep 2020 Planned primary completion date changed from 2 Jul 2021 to 18 Jun 2021.
- 15 Jun 2020 New trial record